Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Alkynes Stories

2012-11-30 08:24:30

ST. PAUL, Minn., Nov. 30, 2012 /PRNewswire/ -- Nearly a quarter of patients taking erlotinib (Tarceva®) for treatment of advanced non-small cell lung cancer (NSCLC) did not receive the recommended pharmacogenomic (PGx) testing prior to the start of treatment, according to a new study by pharmacy benefit manager Prime Therapeutics (Prime), in collaboration with Jonas de Souza, MD, Instructor of Medicine, Section of Hematology/Oncology, University of Chicago Medical Center. The study will...

2012-11-20 08:27:28

NORTHBROOK, Ill., Nov. 20, 2012 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), today announced it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for Tarceva(®) (erlotinib) tablets for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor...

Soldier Beetle Defense Turned Into Biotech Opportunity Through Gene Discovery
2012-11-08 10:31:11

CSIRO Australia New antibiotic and anti-cancer chemicals may one day be synthesized using biotechnology, following CSIRO's discovery of the three genes that combine to provide soldier beetles with their potent predator defense system. CSIRO researchers, and a colleague at Sweden's Karolinska Institute, published details of the gene identification breakthrough and potential applications recently in the international journal Nature Communications. "For the first time, our team has been...

2012-10-24 07:32:04

SAN FRANCISCO, Oct. 24, 2012 /PRNewswire/ -- Sutro Biopharma, a biopharmaceutical company developing a new generation of antibody drug conjugate therapeutics and bifunctional antibody-based therapeutics for targeted cancer therapies, today announced the expansion of its senior management team with the appointments of Jeremy Bender, Ph.D., as chief business officer and Aaron K. Sato, Ph.D., as vice president, research. "These appointments reflect an important step in the growth of our...

2012-10-19 01:42:35

A U.S. Food and Drug Administration-funded study led by the Kaiser Permanente Northern California Division of Research found an increased risk of arterial thrombotic events (ATE) and venous thromboembolic events (VTE) – commonly referred to as blockage of arteries and blood clots, respectively – associated with drospirenone-containing birth control pills compared to four low-dose estrogen combined hormonal contraceptives. "We found that starting use of drospirenone-containing...

2012-10-01 16:12:22

Where are the most promising developments from first-in-human studies? Several new first-in-man studies for drugs targeted against a range of cancers were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna. "These studies represent our first glance at some of the drugs that may improve cancer treatment in coming years," said Prof Ahmad Awada, head of the medical oncology clinic at Jules Bordet Institute, Brussels, Belgium, chair of the ESMO 2012...

2012-08-29 02:25:47

SAN DIEGO, Aug 29, 2012 /PRNewswire/ -- Proacta Incorporated announced today that the US Food and Drug Administration has allowed its Investigational New Drug (IND) Application for PR610, a hypoxia-activated, irreversible multi-kinase inhibitor (MKI) for the treatment of cancer. The IND allowance permits Proacta to initiate human clinical trials of this novel, first in class treatment. Initially, development will focus on patients with non-small cell lung cancer who have developed resistance...

2012-04-30 02:26:05

WALTHAM, Mass., April 30, 2012 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a late-stage oncology company focused on the clinical development of epigenetic therapies in solid tumors, announced that previously reported results from ENCORE 401, a randomized, placebo controlled Phase 2 study of erlotinib with or without entinostat in advanced non-small cell lung cancer patients were published in the Journal of Clinical Oncology (JCO). The article entitled, "Randomized Phase II Trial of...

2012-04-18 20:36:41

Presentation at the 3rd European Lung Cancer Conference Patients with advanced non-small cell lung cancer should only receive treatment with the drug erlotinib before receiving standard chemotherapy if their tumor is known to harbor EGFR mutations, researchers report at the 3rd European Lung Cancer Conference in Geneva, Switzerland. The results of biomarker analyses of a recently reported clinical trial confirm that patients with unknown or negative mutation status should be treated...

2012-04-18 20:29:53

Presentations at the 3rd European Lung Cancer Conference Several new studies that may help doctors tailor lung cancer treatment to the characteristics of individual patients and of their tumors are being presented at the 3rd European Lung Cancer Conference in Geneva. "A major goal of lung cancer treatment is to tailor the treatment to the individual," says Dr Fiona Blackhall from The Christie NHS Foundation Trust in Manchester, UK. "The studies that will be presented at ELCC 2012 are...